查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790439

美國帶狀皰疹疫苗市場規模、佔有率和趨勢分析報告：按產品、疫苗類型、最終用途和細分市場預測，2025 年至 2033 年

U.S. Shingles Vaccine Market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax, SkyZoster), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國帶狀皰疹疫苗市場規模與趨勢：

預計到 2024 年，美國帶狀皰疹疫苗市場規模將達到 34.1 億美元，2025 年至 2033 年的複合年成長率為 10.17%。

市場成長的關鍵促進因素包括老年人口的不斷成長、人們對帶狀皰疹相關併發症認知的不斷提高以及重組疫苗技術的廣泛應用。在預防保健領域，帶狀皰疹疫苗對於減輕50歲及以上成年人（尤其是免疫系統較弱的人群）的疾病負擔至關重要。雙劑型佐劑疫苗的推出提高了疫苗的長期療效和接種率。此外，基於mRNA的帶狀皰疹疫苗的持續研發以及疫苗接種方案的改進，將繼續支持疫苗的接種和市場擴張。

老年人對長期免疫保護的需求日益成長，促使疫苗設計顯著改進，重點在於提高免疫反應和安全性。 Shingrix 等基因定序疫苗已展現出卓越的臨床效果，並廣泛推薦用於美國成年人口。包括基於 mRNA 的製劑在內的新型候選疫苗正在開發中，旨在提供更便捷的給藥方式、更廣泛的免疫保護和更高效的生產流程。這些技術創新預計將在未來幾年增強市場，尤其是在預防性醫療保健需求日益成長的情況下。

支持性的醫療基礎設施和公共衛生政策也在塑造美國帶狀皰疹疫苗的格局。聯邦舉措、成人疫苗宣傳活動以及醫療保險對帶狀皰疹疫苗的覆蓋，改善了老年人的接種途徑，並減少了經濟障礙。隨著癌症、器官移植和慢性疾病導致免疫力缺乏人群的增加，帶狀皰疹疫苗接種已成為臨床指南的強制性組成部分。為此，醫療保健系統正在擴大推廣，並將成人疫苗接種納入常規就診，以符合更廣泛的公共衛生目標。

持續的研發和產品創新投入進一步提高了疫苗的可及性。公私合作和資金投資正在加速臨床試驗，並促進佐劑系統和mRNA平台等先進技術的應用。此外，真實世界臨床試驗提供了長期有效性的證據，支持了疫苗的可信度和廣泛應用。雖然目前美國市場由定序主導，但全球對帶狀皰疹疫苗日益成長的興趣體現在其他地區的新產品核可上，例如SKYZoster，該疫苗於2023年在馬來西亞核准。這些進展預示著未來市場擴張和競爭的潛力。

由於成人疫苗接種日益受到重視、疾病負擔不斷增加以及技術進步，美國帶狀皰疹疫苗市場預計將保持強勁成長。該行業正致力於改善免疫反應、降低給藥複雜性，並透過私人和公共衛生管道擴大推廣。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國帶狀皰疹疫苗市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國帶狀皰疹疫苗市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國帶狀皰疹疫苗市場：產品評估與趨勢分析

  • 2024年及2033年的產品市場佔有率
  • 細分儀表板
  • 美國帶狀皰疹疫苗市場：產品展望
  • 2021年至2033年市場規模、預測與趨勢分析
    • 定序
    • 佐斯塔瓦克斯
    • 天空之星

第5章美國帶狀皰疹疫苗市場：按疫苗類型進行的估計和趨勢分析

  • 2024 年和 2033 年疫苗類型市場佔有率
  • 細分儀表板
  • 美國帶狀皰疹疫苗市場：疫苗類型展望
  • 2021年至2033年市場規模、預測與趨勢分析
    • 重組疫苗
    • 減毒活疫苗

第6章美國帶狀皰疹疫苗市場：最終用途估計和趨勢分析

  • 2024年及2033年最終用途市場佔有率
  • 細分儀表板
  • 美國帶狀皰疹疫苗市場：最終用途展望
  • 2021年至2033年市場規模、預測與趨勢分析
    • 私人醫療機構
    • 政府醫療機構

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • GlaxoSmithKline plc.
    • Pfizer Inc.
    • Merck &Co., Inc.
    • CanSinoBIO
    • Vaccitech
    • Green Cross Corp
    • Geneone Life Science
    • SK Bioscience
Product Code: GVR-4-68040-679-0

U.S. Shingles Vaccine Market Size & Trends:

The U.S. Shingles Vaccine market size was valued at USD 3.41 billion in 2024 and is projected to register a CAGR of 10.17% during 2025 - 2033. Growth in the market is primarily driven by the expanding elderly population, increased awareness of shingles-related complications, and the broader adoption of recombinant vaccine technologies. In preventive healthcare, shingles vaccines are crucial for reducing disease burden among adults aged 50 and above, particularly those with compromised immune function. The introduction of two-dose, adjuvanted formulations has improved long-term efficacy and coverage. In addition, ongoing R&D efforts around mRNA-based shingles vaccines and improved immunization schedules continue to support uptake and market expansion.

The rising need for long-lasting protection in older adults has led to notable improvements in vaccine design, focusing on enhanced immune response and safety. Recombinant vaccines such as Shingrix have shown strong performance in clinical settings. They are widely recommended across the U.S. adult population. Newer vaccine candidates, including mRNA-based formulations, are being developed to offer simpler dosing, broader immune protection, and more efficient production timelines. These innovations are expected to strengthen the market over the coming years, especially as demand for preventive care grows.

Supportive healthcare infrastructure and public health policies also shape the U.S. shingles vaccine landscape. Federal initiatives, adult immunization campaigns, and Medicare coverage for shingles vaccination have improved access and reduced financial barriers for older adults. As the number of immunocompromised individuals rises due to cancer, organ transplants, and chronic conditions, shingles vaccination has become an essential part of clinical guidelines. In response, healthcare systems are expanding outreach, integrating adult vaccines into regular care visits, and aligning with broader public health goals.

Continued investment in R&D and product innovation is further enhancing vaccine availability. Public-private collaborations and funding support are helping accelerate clinical trials and promote the use of advanced technologies like adjuvant systems and mRNA platforms. In addition, real-world studies generate evidence of long-term efficacy, helping drive vaccine confidence and adoption. While Shingrix dominates the current U.S. market, growing global interest in shingles vaccines is reflected in new product approvals elsewhere, such as SKYZoster's approval in Malaysia in 2023. Such developments signal potential for future market expansion and competition.

The growing emphasis on adult vaccination, rising disease burden, and technological progress are expected to sustain strong growth in the U.S. Shingles Vaccine Market. The industry focuses on improving immune response, reducing dosing complexity, and expanding outreach through private and public health channels.

U.S. Shingles Vaccine Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the U.S. Shingles Vaccine market on the product,vaccine type, and end use:

  • Product Outlook (Revenue in USD Million, 2021 - 2033)
    • Shingrix
    • Zostavax
    • SKYZoster
  • Vaccine Type Outlook (Revenue in USD Million, 2021 - 2033)
    • Recombinant Vaccine
    • Live Attenuated Vaccine
  • End Use Outlook (Revenue in USD Million, 2021 - 2033)
    • Private Healthcare Settings
    • Government Healthcare Settings

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Vaccine type
    • 1.2.3. End Use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Vaccine type outlook
    • 2.2.3. End Use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Shingles Vaccine market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Aging Population & Rising Shingles Incidence
      • 3.2.1.2. Government Programs & Outreach Initiatives
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Vaccine Cost & Financial Barriers
      • 3.2.2.2. Vaccine Hesitancy & Logistical Hurdles
  • 3.3. U.S. shingles vaccine market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Shingles Vaccine Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. U.S. Shingles Vaccine Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Shingrix
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Zostavax
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. SKYZoster
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Shingles Vaccine Market: Vaccine type Estimates & Trend Analysis

  • 5.1. Vaccine type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Shingles Vaccine Market by Vaccine type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Recombinant Vaccine
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Live Attenuated Vaccine
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Shingles Vaccine Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. U.S. Shingles Vaccine Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Private Healthcare Settings
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 6.4.2. Government Healthcare Settings
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. GlaxoSmithKline plc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Pfizer Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Merck & Co., Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. CanSinoBIO
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Vaccitech
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Green Cross Corp
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Geneone Life Science
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. SK Bioscience
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Shingles Vaccine Market, by Product, 2021 - 2033 (USD Million)
  • Table 3 U.S. Shingles Vaccine Market, by Vaccine type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Shingles Vaccine Market, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Shingles Vaccine Market: market outlook
  • Fig. 10 U.S. Shingles Vaccine competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Shingles Vaccine Market driver impact
  • Fig. 16 U.S. Shingles Vaccine Market restraint impact
  • Fig. 17 U.S. Shingles Vaccine Market strategic initiatives analysis
  • Fig. 18 U.S. Shingles Vaccine Market: Product movement analysis
  • Fig. 19 U.S. Shingles Vaccine Market: Product outlook and key takeaways
  • Fig. 20 Shingrix market estimates and forecast, 2021 - 2033
  • Fig. 21 Zostavax market estimates and forecast, 2021 - 2033
  • Fig. 22 SKYZoster market estimates and forecast, 2021 - 2033
  • Fig. 23 U.S. Shingles Vaccine Market: Vaccine type movement Analysis
  • Fig. 24 U.S. Shingles Vaccine Market: Vaccine type outlook and key takeaways
  • Fig. 25 Recombinant Vaccine market estimates and forecasts, 2021 - 2033
  • Fig. 26 Live Attenuated Vaccine market estimates and forecasts,2021 - 2033
  • Fig. 27 U.S. Shingles Vaccine Market: End Use movement analysis
  • Fig. 28 U.S. Shingles Vaccine Market: End Use outlook and key takeaways
  • Fig. 29 Private Healthcare Settings market estimates and forecasts, 2021 - 2033
  • Fig. 30 Government Healthcare Settings market estimates and forecasts,2021 - 2033
  • Fig. 31 U.S. Shingles Vaccine Market share and leading players
  • Fig. 32 U.S. market share and leading players
  • Fig. 33 U.S. SWOT
  • Fig. 34 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 35 Market share of key market players- U.S. Shingles Vaccine Market